Jonathan Tobin discusses Atox Bio's Phase 3 results and NDA submission plans
VOX MARKETS
10th July 2020
Jonathan Tobin, PhD, Arix Managing Director and Atox Bio Board Director discusses Atox's Phase 3 results and planned NDA submission in Q3 2020
Stay Updated
Add your email below to stay updated with useful and informative content from Arix and our portfolio companies